Intestinal Rehabilitation Episode 5, Literature Review

Published: 2022-12-01

1 Views

0 Likes

0 Shares

0 Comments

StayCurrentMD

View profile →

Intestinal Rehabilitation: From Crisis Management to Lifelong Care

Episode 5 of 13 in Intestinal Rehabilitation. The through-line across the whole series and where this episode fits in it. Written by Kai from every episode in the series and reviewed before publishing.

Series arc · AI-written, human-reviewed

The through-line

This eleven-episode series argues that intestinal failure in children is no longer a death sentence but a manageable chronic condition—provided the surgical, medical, and nutritional decisions made in the first hours and months are guided by an understanding of intestinal biology rather than visual assessment at laparotomy [e2p1-c23]. The series builds a case for conservative early management, aggressive enteral feeding, multidisciplinary coordination, and patience with the adaptive process [e1-c3]. Survival in major programs now exceeds 90%, and fewer than 2% of patients die from liver disease, yet the path from neonatal catastrophe to enteral autonomy depends on clinicians resisting the impulse to resect aggressively, predict outcomes prematurely, or intervene surgically without understanding what the next three operations will require [e2p2-c3][e4p1-c4].

The progression: from acute crisis to chronic optimization

Episodes 1–2: The foundational argument. The series opens by defining intestinal failure and rehabilitation as a coordinated, time-dependent process requiring enteral nutrition and measured in months to years [e1-c1][e3p1-c2]. Episode 2 immediately confronts the highest-stakes decision: what to do when a preterm infant's bowel appears dead at laparotomy. The answer—clinical observation over visual prediction—sets the tone for the entire series [e2p1-c24]. Helmrath introduces the 50% rule: focal necrosis under 50% of bowel length warrants resection for good adaptive potential, but diffuse necrosis over 50% demands proximal decompression and time [e2p1-c1][e2p1-c14]. The mechanism is liver protection through duodenal decompression, not salvage of questionable bowel [e2p1-c8]. Part 2 extends this to outcomes: ultra-short gut survival is 90–95%, and patients with remnant ileum or colon adapt better than expected [e2p2-c3][e2p2-c7]. The critical teaching is that the 30-week preterm gut has profound regenerative capacity if given luminal nutrition during the steepest growth period—35 weeks gestation to 6 months postnatal [e2p2-c4][e3p1-c23].

Episodes 3–4: The biology and mechanics of adaptation. Episode 3 shifts from crisis to biology. Adaptation is structural (mucosal hypertrophy, angiogenesis, bowel dilation) and functional (slowed motility, upregulated transporters), driven by intraluminal nutrients interacting with trophic peptides [e3p1-c3][e3p1-c4][e3p1-c5]. The ileum adapts better than jejunum because it produces GLP-2, GLP-1, and PYY, which slow motility and signal the liver [e3p1-c8][e3p1-c21]. The colon becomes critical when small bowel remnant falls below 50% of expected length, providing energy from short-chain fatty acids [e3p1-c27]. The new definition of enteral autonomy—independence from parenteral support for 12 weeks with adequate growth and hydration—reframes success around the child's biology, not the calendar [e3p1-c15][e3p2-c23]. Episode 4 translates this into surgical strategy. The STEP procedure works not by creating new bowel but by tapering dilated segments to restore motility [e4p1-c8][e4p2-c1]. Absorptive capacity improves over six months as inflamed mucosa heals [e4p2-c5]. The technical details matter—perpendicular staple lines, 2–2.5 cm caliber, crotch sutures, avoidance of duodenal stapling—but the philosophy matters more: surgery is a game of chess requiring planning two and three steps ahead, and the first operation in the first week of life has lifelong consequences [e4p1-c4][e4p2-c30].

Episode 5: Pharmacologic augmentation. The literature review on teduglutide introduces the only FDA-approved trophic peptide for children. At 0.05 mg/kg, 69% of patients achieved 20% TPN reduction and 10% discontinued TPN entirely [e5-c8][e5-c9]. The mechanism—improved fluid and electrolyte management at the epithelial layer despite GLP-2 receptors not being on enterocytes—underscores that adaptation is a systems problem, not a local one [e5-c17][e5-c18]. The drug requires enteral stimulation to work; the light switch is feeding, the dimmer is the hormone [e5-c13]. This episode also surfaces a recurring theme: fluid management, not calorie absorption, is often the limiting factor in weaning TPN [e5-c15][e5-c20].

Episodes 6–8: Managing complications and the long game. Episode 6 addresses cholestasis, historically a 25–50% mortality driver, now under 2% [e6-c5]. The shift reflects better lipid management (SMOF allows conventional dosing with hepatoprotection), aggressive enteral feeding, and recognition that a bilirubin of 2 mg/dL is transient and does not warrant intervention [e6-c11][e6-c14][e6-c18]. The teaching moment: after jejunostomy takedown, bilirubin and liver enzymes rise transiently as enterohepatic circulation resumes—this is normal, not failure [e6-c19][e6-c20]. Episodes 7 and 8 tackle refeeding in neonates and older children. The neonatal strategy is counterintuitive: high stoma output is an indication to feed, not withhold feeds, because damaged bowel transitions from secretory to absorptive phase only with luminal nutrition [e7-c2][e7-c3]. Breast milk is ideal, but the common mistake is isocaloric TPN reduction when advancing enteral feeds—children with sick intestines do not absorb all calories provided, and total volume may need to expand beyond 140 mL/kg [e7-c10][e7-c13]. For older children who lose bowel to volvulus, the challenge is maintaining nutrition through puberty when energy demands spike; some require temporary return to parenteral support, but marginal gut function often suffices once growth is complete [e8-c21][e8-c22][e8-c24].

The synthesis: what emerges from the whole

Three themes recur across the series, each building on the last. First, time is the variable clinicians control. The gut doubles in length between 35 weeks gestation and one year, and motility matures only with enteral feeding [e4p1-c5][e4p1-c6]. Surgical decisions that preserve bowel length and enable early feeding during this window determine whether a child reaches autonomy [e3p1-c32]. Second, the liver is the gatekeeper. Cholestasis, once a death sentence, is now a manageable complication, but only if duodenal decompression is achieved and enteral feeding is prioritized [e6-c21][e6-c9]. Third, motility trumps length. Very short bowel patients with excellent peristalsis can come off TPN; longer bowel with poor motility cannot [e4p1-c10]. This is why gastroschisis patients underperform despite adequate length—the enteric nervous system is damaged—and why NEC patients do better than expected—they were fed before injury, initiating motility [e4p1-c16][e4p1-c20].

The series also tracks an evolution in surgical philosophy. Early episodes emphasize what not to do: do not resect based on visual assessment, do not create stomas that lose abdominal domain, do not perform STEP in the first year if motility has not matured [e2p1-c23][e2p1-c18][e4p1-c19]. Later episodes shift to what to do: place a G-tube at the first operation for feeding versatility, use Blake drains for proximal decompression, plan staged procedures rather than attempting comprehensive repair [e7-c29][e2p1-c23][e4p2-c9]. The unifying principle is that intraoperative decisions have lifelong impact, and the surgeon's role is not to be the hero but to set up the next operation [e4p2-c30][e4p2-c29].

What the series does not cover

The series is silent on intestinal transplantation beyond acknowledging it as part of the continuum of care [e2p1-c2]. It does not address the psychosocial burden on families managing home TPN, central line care, or the transition to adult care. Neurocognitive outcomes are mentioned optimistically—most children are "running and playing"—but the series does not quantify deficits or explore educational support needs [e2p2-c12]. The role of the microbiome is acknowledged (shifts to acid-producing flora, bacterial overgrowth as a driver of staple-line ulcers) but not deeply explored [e3p1-c28][e4p2-c12]. Finally, the series does not grapple with resource disparities: the multidisciplinary model described requires subspecialty access, home nursing, and insurance coverage that many families lack.

The argument the series makes

Intestinal failure is a chronic disease of childhood, not an acute surgical problem. The first four months of life are when care is most uncoordinated and surgical decisions most consequential [e4p1-c4]. Success requires resisting the impulse to do everything at the first operation, trusting the regenerative capacity of the neonatal gut, feeding early and aggressively despite high output, protecting the liver through duodenal decompression, and planning surgeries in sequence rather than isolation. The outcome—over 90% survival, 60–80% enteral autonomy, normal growth in most—is achievable, but only if clinicians allow the child's clinical trajectory, not their visual assessment or institutional tradition, to guide care [e3p1-c19][e2p1-c24].

Inside this episode

Kai, the Library's AI content creator, listened to this episode and mapped who's speaking, the chapters, key claims, and cases. Every item links to the exact moment in the recording.

AI-enriched

Who's speaking

Ellen Ancisco — host
Paul Wales — guest_expert
Michael Helmrath — guest_expert
Cecilia Jigena — host

Chapters

0:04Introduction and Episode Overview — Hosts introduce the fifth episode in the intestinal rehabilitation series, featuring Dr. Paul Wales and Dr. Michael Helmrath from Cincinnati Children's Hospital. The episode will cover two papers on medical treatment for intestinal rehabilitation.
1:43Teduglutide Phase 3 Trial Results and Patient Selection — Discussion of the 24-week phase 3 study of teduglutide (GLP-2 analog) in pediatric short bowel syndrome. Dr. Wales presents trial outcomes, dosing, patient selection criteria, and the importance of enteral stimulation in conjunction with pharmacologic therapy.
4:29Mechanism of Action and Fluid Management — Dr. Helmrath explains that GLP-2 receptors are not on enterocytes but work at the epithelial layer to improve fluid secretion control. The discussion emphasizes that fluid and electrolyte management, rather than pure nutrition, is often the limiting factor in intestinal rehabilitation.
5:49Enteroendocrine Cell Biology and Nutrient Sensing — Discussion of the second paper on enteroendocrine cells and their role in coupling nutrient sensing to absorption through ion transport regulation. Dr. Helmrath discusses the 20+ subtypes of enteroendocrine cells, CFTR transporters, and the broader implications for secretory diarrhea management.
8:17Summary and Closing — Hosts summarize the key points: enteroendocrine cells secrete peptides that aid nutrient absorption, GLP-2 analogs help with fluid/electrolyte management, and optimizing enteral absorption is key for intestinal failure patients. Emphasis on multidisciplinary team approach.

Key claims

1:48The only trophic peptide currently approved for children is a GLP-2 analog. — Paul Wales
2:06GLP-2 is produced and released by enteroendocrine cells in the distal ileum and right colon. — Paul Wales
2:15GLP-2 has a stimulatory effect on the GI tract. — Paul Wales
2:18Capacity to produce enough GLP-2 to become independent of parenteral support depends on anatomical subtype. — Paul Wales
2:30The trial presented was a 24-week study that follows the Carter paper, which was a 12-week study. — Paul Wales
2:38Two doses of teduglutide were studied: 0.025 mg/kg and 0.05 mg/kg, compared to standard of care. — Ellen Ancisco
2:59Both doses showed benefit, but the 0.05 mg/kg dose showed greater benefit. — Paul Wales
3:07At the 0.05 mg/kg dose, 69% of patients achieved the trial endpoint of 20% reduction in TPN support. — Paul Wales
3:0710% of children in the trial got off TPN completely. — Paul Wales
3:19A more recent paper from Spain showed even more optimistic real-life results with teduglutide. — Paul Wales
3:31Patient selection for teduglutide requires medical stability. — Paul Wales
3:34Starting teduglutide therapy requires families that understand it will require more frequent visits and assessments. — Paul Wales
3:52Adaptation is driven by trophic peptides in conjunction with enteral stimulation. — Paul Wales
4:04The light switch is turned on by feeding, but the amount of light is gradually adjusted based on hormones augmented by GLP-2. — Michael Helmrath
4:17For teduglutide to work, there must be something for the gut to absorb; TPN should be supplementation, not total nutrition. — Ellen Ancisco
4:29Management of fluids presents the greatest challenge in intestinal rehabilitation, and teduglutide helps control this. — Michael Helmrath
4:45GLP-2 receptors are not on the enterocyte, yet clinical improvement in secretory effects occurs at the epithelial layer. — Michael Helmrath
5:09GLP-2 analogs work by helping to reclaim fluid that results from feeds. — Cecilia Jigena
5:18Patients who benefit most from GLP-2 analogs are those whose limiting factor is fluid and electrolyte management. — Cecilia Jigena
6:26At least 20 different types of enteroendocrine cells exist in the intestine. — Michael Helmrath
6:35Fluid regulation inside cells involves electrochemical shifts from transporters like CFTR. — Michael Helmrath
6:44Transporters that are key to nutrient absorption are regulated by hormones like peptide YY. — Ellen Ancisco
7:01The strategy of when to introduce GLP-2 analogs should be sooner than later, but not blindly done, to take advantage of early intestinal growth and development. — Michael Helmrath
7:36The number one cause of death of children in the world is fluid losses from diarrhea and malnutrition. — Michael Helmrath
7:45Understanding fluid and electrolytes will benefit a wider population than just those with intestinal failure. — Michael Helmrath

Open questions

How to utilize peptide hormones in synergy with other therapies to achieve better outcomes in intestinal rehabilitation
What is the optimal timing for introducing GLP-2 analogs in the natural progression of intestinal adaptation
Can patients who are 100% PN dependent benefit from teduglutide therapy

This episode was analyzed and enriched by Kai, the Library's AI content creator. Every item links to the moment it comes from — click a timestamp to listen in context.

Written for:

GLP-2 Analog Therapy in Pediatric Intestinal Failure: Selection and Mechanism

The episode's teaching points arranged as a structured lesson, building from the basics up to the finer points. Written by Kai from the episode transcript and reviewed before publishing.

For the care team · Teaching arc · AI-written, human-reviewed

This discussion unpacks when and how teduglutide works in children with intestinal failure, moving from patient selection through mechanism to the clinical challenge the drug actually solves.

Adaptation requires both enteral stimulation and hormonal amplification. Feeding turns on the adaptation process — that is the light switch 3:52. But trophic peptides like GLP-2 control the intensity of that adaptation, gradually turning the light up or down [q2]. A child on 100% parenteral nutrition has the switch in the off position; teduglutide cannot amplify a signal that is not present. The gut needs something to absorb for the drug to work 4:17. This is why patient selection begins with ensuring some enteral intake exists, even if TPN remains the dominant source of nutrition.

The ideal candidate is medically stable with fluid-electrolyte limitation as the primary barrier. Medical stability is the first gate 3:31. The second is recognizing what actually limits the patient's progress. Children who benefit most are those whose primary problem is reclaiming the fluid that results from feeds, not those with complete malabsorption 5:18. At the 0.05 mg/kg dose, 69% of patients achieved a 20% reduction in TPN support 3:04, but the endpoint reflects fluid and electrolyte control more than caloric independence. Fluid management presents the greatest challenge in these patients 4:29, and teduglutide helps control that 4:29 [q3].

The mechanism is indirect but clinically potent. GLP-2 receptors are not located on the enterocyte 4:45, yet the drug improves secretory effects at the epithelial layer 4:58. It works by helping to reclaim fluid from feeds 5:11, addressing the high-output secretory state that defines short bowel syndrome. This is not intuitive — the hormone does not act where you would expect it to — but the clinical effect is reproducible. Understanding this mechanism clarifies why the drug works best in patients whose limiting factor is fluid loss rather than nutrient absorption failure.

Timing matters: introduce therapy early enough to capitalize on growth. The intestine grows and develops most actively early in life. Therapy should be introduced sooner than later, but not blindly 7:01. The strategy is to use GLP-2 analogs to achieve fluid control early, enabling better enteral nutrition, which in turn supports gut growth during the window when adaptation potential is highest. Delaying until a child is older and medically complicated wastes that window. But starting without ensuring enteral stimulation is present wastes the drug.

This is a problem with implications beyond intestinal failure. The number one cause of death in children worldwide is fluid losses from diarrhea and malnutrition 7:36. Understanding fluid and electrolyte regulation at the epithelial level — how enteroendocrine cells, transporters like CFTR, and hormones like peptide YY interact 6:35 6:44 — will benefit a far wider population than the small cohort with intestinal failure 7:45. The lesson here is not just about when to start teduglutide. It is about recognizing that fluid reclamation, not caloric absorption, often determines whether a child can advance enterally, and that hormonal modulation of that process is now a tool we can deploy systematically rather than waiting passively for adaptation to occur.

GLP-2 Analogs in Pediatric Intestinal Failure: Mechanism and Patient Selection

The episode's teaching points arranged as a structured lesson, building from the basics up to the finer points. Written by Kai from the episode transcript and reviewed before publishing.

For trainees · Teaching arc · AI-written, human-reviewed

Adaptation requires both substrate and signal

Intestinal adaptation in short bowel syndrome depends on two components working together: enteral stimulation and trophic peptides 3:52. One of the discussants used a light switch analogy to clarify this relationship: feeding turns on the switch, while hormones augmented by GLP-2 gradually adjust the intensity 3:52. This means a child who is 100% TPN-dependent cannot benefit from teduglutide — the gut needs something to absorb for the drug to work, with TPN serving as supplementation rather than total nutrition 4:17. The implication for practice is straightforward: before starting therapy, establish at least some enteral intake.

The primary benefit is fluid reclamation, not nutrient absorption

Fluid management presents the greatest challenge in these patients 4:29, and teduglutide's most clinically significant effect is helping to control that challenge 4:29. The mechanism is counterintuitive: GLP-2 receptors are not located on enterocytes 4:45, yet the drug improves secretory effects at the epithelial layer 4:58. What it does is help reclaim fluid that results from feeds 5:11. This means the patients who benefit most are those whose limiting factor is fluid and electrolyte management rather than an absolute inability to absorb nutrients 5:18. If a child is well-nourished but cannot tolerate enteral advancement because of high stool output and electrolyte losses, that is your ideal candidate.

Patient selection requires medical stability and family capacity

Beyond the physiologic requirements, patient selection requires medical stability 3:31. Starting teduglutide during an acute illness or in a child with uncontrolled sepsis will not yield benefit and may complicate management. The therapy also requires more frequent visits and assessments 3:34, which means family engagement is not optional — it is part of the selection criteria. A family that cannot commit to the monitoring schedule should not start the drug, regardless of how well the child fits the physiologic profile.

Efficacy data support the higher dose

The 24-week trial studied two doses: 0.025 mg/kg and 0.05 mg/kg, both compared to standard care 2:48. Both doses showed benefit, but 0.05 mg/kg showed greater benefit 2:59. At that higher dose, 69% of patients achieved a 20% reduction in TPN support 3:04, and 10% of children discontinued TPN entirely 3:04. A subsequent real-world study from Spain showed even more optimistic results 3:19. The lesson is that if you are going to use the drug, use the dose that has demonstrated superior efficacy — there is no reason to underdose.

Timing matters: introduce therapy early but not blindly

One of the discussants emphasized that therapy should be introduced sooner rather than later, but not blindly 7:01. The rationale is developmental: the intestine's capacity for growth and adaptation is greatest early in life, and prolonged dependence on TPN without enteral stimulation limits that window. However, "sooner" does not mean "immediately after resection" — it means as soon as the child is medically stable and has established some enteral tolerance. The goal is to take advantage of the natural adaptation process while the gut is still capable of robust growth.

The broader lesson: fluid and electrolyte management is foundational

The number one cause of death in children worldwide is fluid losses from diarrhea and malnutrition 7:36. Understanding fluid and electrolytes will benefit a wider population than just intestinal failure patients 7:45. The discussants framed teduglutide not as a niche therapy for a rare condition, but as a tool that clarifies fundamental principles of gut physiology — principles that apply to secretory diarrhea, malabsorption, and any condition where fluid balance determines outcome. If you learn to manage fluid reclamation in short bowel syndrome, you have learned something that will serve you across pediatric gastroenterology and surgery.

Takeaways from this story

Teduglutide requires enteral intake to work — TPN must be supplementation, not total nutrition.
The drug's primary benefit is fluid reclamation, not nutrient absorption; ideal candidates are limited by fluid losses.
At 0.05 mg/kg, 69% of patients achieved 20% TPN reduction; use the higher dose that showed superior efficacy.
Start therapy early in medically stable patients with family capacity for frequent monitoring, not blindly after resection.

Topic overview

This journal club discusses two papers on medical management of pediatric intestinal failure. The primary focus is a phase 3 trial of teduglutide (a GLP-2 analog) showing that 69% of patients on the 0.05 mg/kg dose achieved ≥20% reduction in parenteral nutrition support over 24 weeks, with 10% discontinuing TPN entirely. Patient selection requires medical stability, enteral feeding capacity, and families prepared for frequent monitoring. A second paper explores the underlying biology: enteroendocrine cells and their peptide hormones regulate fluid and electrolyte transport at the epithelial level, explaining why GLP-2 analogs particularly benefit patients whose limiting factor is fluid/electrolyte management rather than pure caloric absorption.

Key takeaways

69% of patients on teduglutide 0.05 mg/kg achieved ≥20% TPN reduction; 10% discontinued TPN entirely over 24 weeks. (3:07)
Teduglutide works best when fluid/electrolyte management—not caloric absorption—is the limiting factor in weaning TPN. (4:29)
Patient selection requires medical stability, enteral feeding capacity, and families prepared for frequent monitoring. (3:31)
GLP-2 analogs regulate fluid reclamation at the epithelial level despite receptors not being on enterocytes themselves. (4:45)
Early introduction of GLP-2 analogs may leverage intestinal growth windows, but timing must be individualized, not routine. (7:01)

Keywords

intestinal failure short bowel syndrome secretory diarrhea malnutrition parenteral nutrition TPN enteral feeding teduglutide Gattex Rebusto GLP-2 analog peptide YY Cincinnati Children's Hospital

Hashtags

#IntestinalRehabilitation #ShortBowelSyndrome #PediatricSurgery #TPN

Transcript

Click "Show Transcript" to view the full text (8940 characters)

Hi everyone. Welcome back. This is a stay current podcast. This week we're coming back with another installment in our series with intestinal rehabilitation. Again, we're talking to two of the experts in intestinal rehabilitation from Cincinnati Children's Hospital. We have Dr. Paul Wales, the current surgical director. I'm Paul Wales. I'm a pediatric surgeon here at Cincinnati Children's Hospital, and Dr. Michael Helmrath, the prior surgical director. I'm Michael Helmrath. I'm a pediatric surgeon also doing intestinal. Your surgery and research here at Cincinnati Children. I'm Ellen Ancisco. I'm Cecilia Jigena, and we're with the stay current team. And so this week we're kind of doing a journal club here. We're going to talk about two articles, and really they're related to medical treatment for intestinal rehab. One of the article is about a GLP-2 analog, and the second paper talks about the enter endocrine cells and the peptides that secrete that helps manage the fluids and Electrolytes to help absorb nutrients in these patients. OK, so we'll dive into the first article. It's called Safety and Efficacy of taglutide in Pediatric Patients with Intestinal failure Due to Short Bowel syndrome, a 24 week phase 3 study, and Dr. Wales is actually an author on this paper. It was published in the Journal of Parenteral Enteral Nutrition back in May of 2020. The papers that we talk about are linked below so you can take a look for yourself. Dr. Wales started out by telling us why this research is important. One of the tools that intestinal rehab programs have is pharmacologic therapy. One category of therapies are the trophic peptides, and the only trophic peptide that is currently approved for children is GLP-2 analog. And GLP-2 analog is called tedulutide. Gattex is one of the brand names, and Rebusto is what they. in Canada and some other places, GLP-2 is produced and released by the enteroendocrine cells in the distal ileum in the right colon. It has a stimulatory effect on the GI tract. Depending on your anatomical subtype, you have a better capacity to produce enough GLP-2 to become independent of parenteral support. Let's talk about the paper. The trial that is in the paper that we're presenting was a 24 week study which Follows the Carter paper, which was a 12-week study. And so basically this study was looking at a couple of different doses of taglutide, and in this paper two doses were used. So we had either 0.025 mg per kilogram or 0.05 mg per kilogram of taglutide compared to the standard of care, i.e., not receiving taglutide. Both showed benefit, but the 0.05 dose showed a greater benefit. And And what happened to these patients? At the 0.05 dose, 69% of patients achieved the endpoint of the trial, which was a 20% reduction in TPN support, and 10% of kids total got off TPN. And, and then the more recent paper out of Spain, which was like a real-life experience, showed even more sort of optimistic results. which patients can actually benefit from this. You want to select patients that are medically stable. And the other consideration here is you need a family that realizes that when you start this therapy, it's going to require more frequent visits and assessments, so a kid who's 100% PN dependent. Can they go on Gads? In case you forgot, that was Doctor Michael Holmbraath. You know, if we think about adaptation, what drives adaptation is, you know, trophic peptides is one of the parts of, of the process, but that's usually in conjunction with enteral stimulation. That's an important concept that's hard to teach. The fact that the light switch. is turned on by feeding, but the, the amount of light in the room is gradually turned up or down based on the hormones that are augmented by GLP-2. That's another great point that you have to, even if these kids, you know, need TPN, they need it as supplementation, not for their total nutrition. There has to be something for the gut to absorb in order for the drug to work. Nutrition is key to growing and developing them. But the management of the fluids really presents us with the greatest challenge, and that's been one of my my impressions that this medicine really helps us start to control that. So I think it's important to talk about mechanism. You alluded to the fact that the receptors for GLP-2 are not on the enterocyte, and yet what we're seeing clinically is. That the secretory effects of short bowel that result in the high fluid secretions that challenge all of us are improved at the epithelial layer. So to explain this. What he's saying is that TLP2 analogs work by helping to reclaim the fluid that results from feeds. And so the patients that will benefit more from this are those who are in the situation whereby the limiting factors to moving ahead are the fluid and electrolytes management. And so the challenges for the next decade, I think, involve these peptide hormones. How to utilize them in synergy with therapies that are going to give us the better outcomes. OK, so that was our first paper. Let's see what we have next. And this paper that Dr. Holmrath is an author of is called Enteroendocrine Cells Couple Nutrient Sensing to Nutrient Absorption by Regulating Ion Transport, and this was published in Nature Communications also back in 2020. Studies like this that allow us to study specific human conditions that can't be mimicked in animal. Models give us insight into understanding the nutrient sensing that we need to understand in managing these patients and probably more broadly patients with secretory diarrhea and other conditions. Endocrine cells actually there's many different subtypes. We know at least 20 different types of, uh, endocrine cells that exist in there. What regulates the, the fluid inside the cell. To do with the electrochemical shifts that occur from transporters like CFTR. Right, he's talking a lot about kind of the underlying biology for why all of this works, why all this is important, and so he's saying that these transporters that are a key part of nutrient absorption, they are regulated by these hormones like peptide YY. But the natural history of this. is to understand the progression that happens early in life that you want to take advantage of in the intestine growing and developing and the strategy of when to introduce these things, as Paul was saying, should be sooner than later, but not just blindly done. And we need to like have good nutrition in order for the gut to grow, and so I think what he's saying, we have to, you know, treat the kids early enough that they have the benefit. Of these GLP-2 analogs so that they can be well nourished, grow, and in the future, ideally not have this problem. I would remind people that the number one cause of death of children in the world is fluid losses from diarrhea, malnutrition, and other, other conditions. So understanding just fluid and electrolytes and how to grow healthy is going to benefit a wider population. By far than what we think about with intestinal failure, and as a surgeon, you have to be part of the team. Again, I feel like we in this podcast series, we are always talking about nutrition. We're always also talking about how important multidisciplinary teams, so we need teamwork of peptides and hormones. We also need the teamwork of practitioners, gastroenterologists, nutritionists, dietitians, surgeons. The list goes on OK, so, it's a pretty dense discussion we've had during today. How would you summarize it, Cecilia? OK, so I will summarize it by saying that we have a lot of peptides that the enteroendocrine cells secrete that help with the absorption of nutrients in the gut. And then we have this GLP2 analog that can help our patients with the fluid and electrolyte management. So these patients that have problems with enteral nutrition because they can't manage their fluids will benefit from this drug and really, you know, we talked about a couple of papers here, one, a more clinical application of GLP-2 analogs and how using them in patients who can actually decrease their needs for TPN and maybe even get off of TPN. And then another one kind of talking about the underlying biology with Dr. Helmrath, you know, one of the key issues is, is really their absorption of nutrients in the gut and so enhancing that, optimizing that. This turned out to be really key for these kids with intestinal failure. We'll see what comes next. Yeah, perfect. Stay tuned for more episodes like this. We're gonna continue having conversations with Doctor Wales and Doctor Helm Roth. If you liked what you heard, don't forget. Leave us a rating or review on Apple Podcasts or Spotify, wherever you're listening. Don't forget to subscribe to our YouTube channel and download the Stay Current in Pediatric Surgery app. It has all these podcasts, videos, a lot more. Until next time, I'm Ellen and Cisco, and I'm Cecilia Geno. This is the Stay Current podcast.

Comments

Loading comments...